TY - JOUR
KW - United States
KW - Treatment
KW - Multidrug-resistant
KW - Multidrug therapy
KW - leprosy
KW - Drug Resistance
AU - Williams DL
AU - Hagino T
AU - Sharma R
AU - Scollard D
AB - TO THE EDITOR: Since the initiation of multidrug therapy for leprosy (Hansen disease) in the 1980s by using rifampin, dapsone, and clofazimine, resistance to rifampin and dapsone has been observed worldwide and is still prevalent (1,2). Because few alternative effective antileprosy drugs exist, resistance to these first-line drugs could seriously affect leprosy control programs. We report a documented case of primary multidrug-resistant (MDR) leprosy in the United States.
BT - Emerging infectious diseases
C1 - http://www.ncbi.nlm.nih.gov/pubmed/23260417?dopt=Abstract
CN - WILLIAMS 2013
DA - 2013 Jan
DO - 10.3201/eid1901.120864
IS - 1
J2 - Emerging Infect. Dis.
LA - eng
N2 - TO THE EDITOR: Since the initiation of multidrug therapy for leprosy (Hansen disease) in the 1980s by using rifampin, dapsone, and clofazimine, resistance to rifampin and dapsone has been observed worldwide and is still prevalent (1,2). Because few alternative effective antileprosy drugs exist, resistance to these first-line drugs could seriously affect leprosy control programs. We report a documented case of primary multidrug-resistant (MDR) leprosy in the United States.
PY - 2013
SP - 179
EP - 81
T2 - Emerging infectious diseases
TI - Primary multidrug-resistant leprosy, United States.
UR - http://wwwnc.cdc.gov/eid/article/19/1/pdfs/12-0864.pdf
VL - 19
SN - 1080-6059
ER -